The study found that intratumoral Fusobacterium is associated with a more aggressive subtype of colorectal cancer characterized by limited immune response and increased disease recurrence. The presence of this bacterium also predicts poorer outcomes with adjuvant chemotherapy.
A phase III clinical trial shows that [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) compared to everolimus. Radioligand therapy targets somatostatin receptors, minimizing damage to surrounding healthy cells.
A VHIO-led study identifies epigenetic changes caused by diet, tobacco, and pesticide exposure as risk factors for early-onset colorectal cancer. The study, published in Nature Medicine, confirms the influence of lifestyle and environmental exposures on cancer development in younger patients.
Researchers have developed an ultrasensitive liquid biopsy platform to predict and monitor immunotherapy response in advanced cancer patients. The study shows that lower levels of circulating tumor DNA (ctDNA) at baseline are associated with better progression-free survival and overall survival.
Researchers present phase 1 study results of rapcabtagene autoleucel, a rapid CAR-T cell manufacturing platform that reduced production time to under two days. The treatment showed a manageable safety profile and promising antitumor activity, with complete remission rates ranging from 70% to 100% in patients.
Omomyc, a direct MYC inhibitor, causes DNA damage in cancer cells and potentiates antitumor response when combined with PARPi inhibitors. This synergy offers a new therapeutic opportunity to overcome PARPi resistance in triple-negative breast cancer.
A sub-study of KEYMAKER-U03 found pembrolizumab-based triplet combinations to be effective in treating advanced renal cell carcinoma, with an objective response rate of 78% and a median progression-free survival of 31.8 months. The most promising combination included pembrolizumab, belzutifan, and lenvatinib.
Researchers have discovered a new approach to combating drug resistance in advanced prostate cancer, combining CDK4/6 inhibitors with senolytic therapies. The sequential treatment strategy has shown potential in preclinical models, highlighting the possibility of improved clinical outcomes and new avenues for repurposing CDK4/6i therapy.
The combination of dual-targeted therapies with encorafenib and cetuximab plus chemotherapy significantly improved outcomes in previously untreated patients with metastatic colorectal cancer, doubling overall survival. Improved progression-free survival was also observed, reducing the risk by 47%.
A new AI tool, SALSA, has been developed to automate the detection and monitoring of liver tumors with high precision. The tool, which uses deep learning algorithms, demonstrates superior accuracy in cancer detection and quantification of tumor burden, surpassing state-of-the-art models.
Researchers discover that oxygen-starved cancer cells use the same gene as high-altitude populations, such as Tibetans and Sherpas, to adapt to hypoxia. This convergence in genetic adaptation could lead to new therapeutic targets for cancer treatment.
A new study found that RAD51 testing can complement next-generation sequencing in personalizing prostate cancer treatment, especially for patients with homologous recombination repair-defective tumors. The biomarker showed high sensitivity and specificity for identifying BRCA1/2 alterations.
A study found that RAD51 testing can predict which patients with early-stage HER2-negative breast cancer may respond to neoadjuvant therapy. Patients with high RAD51 protein levels showed a higher response rate to PARP inhibitor treatment, suggesting the potential for personalized treatment strategies.
A novel CAR T-cell therapy targeting p95HER2-expressing cells demonstrates complete and durable antitumor responses in a subset of HER2+ tumors, raising hopes for improved cancer treatment. The therapy also activates immune cells within the tumor microenvironment, showing promising results.
Researchers have found that combining the VIGex gene expression signature with liquid biopsy analysis improves response prediction to immunotherapy in patients with advanced solid tumors. The study analyzed tumor samples and circulating tumor DNA (ctDNA) by liquid biopsy, showing that the VIGex-Hot subgroup was associated with higher o...
Researchers found saruparib to be superior and durable in treating PDX models with BRCA1/2 alterations, outperforming olaparib in terms of complete response rate and progression-free survival. The study's results suggest the promise of PARP1 selective inhibitors as a new therapeutic option for patients with advanced solid tumors.
Researchers have generated the largest collection of patient-derived mouse models to study pseudomyxoma peritonei, a rare cancer with few treatment options. They found that BRAF inhibitor encorafenib significantly reduced tumor growth and prolonged survival in mice.
Researchers developed a novel liquid biopsy technique to monitor disease evolution in metastatic prostate cancer patients. The method analyzes DNA and RNA in circulating extracellular vesicles, capturing tumor genomics and transcriptomic changes.
Researchers demonstrate the utility of analysing circulating tumor DNA (ctDNA) through a high-sensitivity liquid biopsy platform, allowing for early prediction of treatment response and prognosis. The study shows that detecting low levels of ctDNA can predict longer progression-free survival and overall survival.
The first phase 1 trial of the bispecific antibody FS222 demonstrates promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy. Preliminary results show partial or complete objective response rates in various tumor types.
A combination of amivantamab and lazertinib shows benefits over standard treatment in a subgroup of patients with advanced lung cancer, particularly those with poor prognostic markers. The new therapeutic strategy reduced the risk of disease progression and death by 30% compared to osimertinib.
A novel AI-based and non-invasive diagnostic tool, DISCERN, enables accurate brain tumor diagnosis with high accuracy, surpassing conventional methods. The tool leverages deep learning to identify behavioral patterns on imaging specific to each tumor.
A Phase I first-in-human clinical trial has demonstrated the safety and anti-tumor activity of OMO-103, a novel MYC inhibitor. The study showed favorable safety profile with only mild side effects, and notable clinical benefits in patients, including disease stabilization and tumor shrinkage.
A study found that patients with refractory large B-cell lymphoma who received bendamustine before CAR T-cell therapy had a shorter progression-free survival and overall response rate compared to those who did not receive bendamustine. The use of bendamustine should be avoided in these patients when possible.
A Phase IIa international study found that a combination of zanidatamab, palbociclib, and fulvestrant improved progression-free survival by 12 months with durable responses. The treatment regimen is being developed for heavily pretreated patients with HER2+/HR+ metastatic breast cancer.
Adding immunotherapy atezolizumab to chemotherapy and bevacizumab improved overall survival by 32.1 months compared to 22.8 months with standard therapy alone. The two-year survival rate was also higher, with 60% in patients treated with the experimental combination.
Researchers found that monotherapy with PARP inhibitor olaparib improved radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer who have BRCA gene mutations. Improved responses were observed in hereditary BRCA mutations as well as spontaneous alterations.
Researchers developed VIGex, a gene expression signature predicting patients' response to immunotherapy. The tool classifies solid tumors into three categories based on the inflammatory status of the tumor microenvironment, helping identify patients most likely to benefit from immune-based therapies.
A VHIO-led study has identified DPPA3 as a regulator of dormant cancer cells and chemoresistance in colorectal cancer. High levels of DPPA3 are found to predict disease relapse, while HIF1 is proposed as a potential therapeutic target to sensitize CRC cells to chemotherapy.
Breast milk from breast cancer patients contains tumour DNA that can be detected through liquid biopsy, offering a potential new tool for early diagnosis. The study found that ctDNA was detectable in 13 of 15 breast milk samples collected from breast cancer patients, outperforming detection in blood samples.
RAGE signaling maintains mesenchymal state of TNBC cells by enforcing SNAIL1 protein expression, promoting tumor cell proliferation and invasion. Inhibiting RAGE with a pharmacological antagonist reduces tumor cell plasticity and improves survival in xenograft mouse models.
A first-in-human study demonstrates the efficacy of a novel PRMT5 inhibitor, JNJ-64619178, in treating advanced solid tumors. The treatment showed manageable dose-dependent toxicity and achieved preliminary antitumor activity in patients with various cancer types.
The FRESCO-2 phase III study demonstrated statistically significant improvements in overall survival and progression-free survival in patients with refractory metastatic colorectal cancer treated with fruquintinib. Fruquintinib showed a favorable safety profile, with patients staying on treatment almost twice as long as those on placebo.
A phase I study found significant clinical benefit of the ADC luveltamab tazevibulin in patients with recurrent ovarian cancer expressing high levels of folate receptor alpha, with an overall response rate of 37.5% and a 44% response rate at higher doses.
A new liquid biopsy approach, ACT-Discover, shows improved sensitivity in detecting tumor DNA in blood for pancreatic cancer patients. The technique analyzes genomic and molecular characteristics over time to advance insights into disease evolution.
A new MYC inhibitor, Omomyc, has shown promising preclinical results in reducing melanoma tumor growth and metastatic capacity by halting the transcription of genes implicated in cell growth and proliferation. The study demonstrates a good prognostic gene signature in melanoma patients with this approach.
Researchers discovered over 500 non-canonical protein-derived peptides that could be recognized by T-cells, but found no spontaneous immune response. Three novel T-cell receptors were identified for specific non-canonical HLA-I tumor ligands with promising tumor specificity.
The CALYPSO study assesses the efficacy of combined MET and PD-L1 inhibition in patients with MET-driven metastatic papillary renal cancer. Response rates were 29% for all patients and 53% for those with MET-driven tumors, with improved progression-free survival observed in MET-driven status.
Pharmacokinetic analysis reveals Omomyc's lasting anti-cancer effects, with structural integrity persisting in tumor tissue for at least 72 hours. This finding is significant for clinical trials evaluating Omomyc as a MYC inhibitor.
The SERENA-2 trial found camizestrant significantly improves progression-free survival versus fulvestrant in patients with estrogen receptor-positive, HER2-negative breast cancer. Camizestrant demonstrates efficacy across various patient populations, including those with ESR1 mutations and prior CDK4/6 inhibitor treatment.
Researchers at VHIO have established a unique collection of metastatic cholangiocarcinoma patient-derived xenografts to help prioritize potential clinical trials and deliver precision patient care. The models have identified mutations in genes such as BRCA2, which could serve as a biomarker for response to PARP inhibitors.
A phase I clinical trial found that Omomyc (OMO-103) has few side effects and can stabilize disease in some patients. The treatment showed stabilization of disease in 8 out of 17 evaluable patients, including one patient with pancreatic cancer who remained on the study for over six months.
A new predictive biomarker, RNF43 mutations, has been identified as a significant predictor of response to anti-BRAF/EGFR combinatory therapy in patients with microsatellite stable BRAF V600E metastatic colorectal cancer. This biomarker is associated with improved progression-free and overall survival rates.
A novel T cell bispecific antibody targeting EGFRvIII mutant glioblastoma has demonstrated potent anti-tumor activity in preclinical models. The therapy harnesses the power of the immune system to selectively target and destroy cancer cells, offering a safer treatment option for patients.
A novel BRAF inhibitor, C1a, has been developed to cross the blood-brain barrier and treat melanoma brain metastasis. The study found that C1a triggered robust responses in patient-derived models and outperformed approved BRAF inhibitors, achieving significant increases in survival rates.
Follow-up data from the COSMIC-311 study confirm cabozantinib's superiority over placebo in patients with progressive differentiated thyroid cancer, with significant improvements in progression-free survival across all tumor subtypes. The treatment also demonstrated manageable safety and efficacy in a diverse patient population.
Researchers found that MYC inhibition by Omomyc exerts a dramatic effect on the metastatic process, reducing primary tumor and metastatic growth. The study suggests that MYC inhibition is anti-metastatic in breast cancer, offering promise as an anti-metastatic therapy.
Results from the Phase III EMPOWER trial demonstrate the efficacy of PD-1 inhibitor cemiplimab in improving overall survival for women with recurrent and/or metastatic cervical cancer. The study showed a 31% lower risk of death in patients receiving cemiplimab compared to chemotherapy.
A study published in Clinical Cancer Research shows that matched targeted therapy according to ESCAT's ranking of genomic alterations significantly improves survival of cholangiocarcinoma patients. Patients with ESCAT tier I-II alterations had longer median overall survival compared to those with non-actionable alterations.
The KEYNOTE-811 trial demonstrates a significant improvement in objective response rate (74.4%) and tumor size reduction compared to trastuzumab and chemotherapy. The combination of pembrolizumab, trastuzumab, and chemotherapy markedly reduces tumor size and induces complete responses in some patients.